Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Change in Account Payables (2016 - 2025)

Assembly Biosciences (ASMB) has 11 years of Change in Account Payables data on record, last reported at $940000.0 in Q3 2025.

  • For Q3 2025, Change in Account Payables rose 76.03% year-over-year to $940000.0; the TTM value through Sep 2025 reached $348000.0, down 39.69%, while the annual FY2024 figure was $124000.0, 106.1% up from the prior year.
  • Change in Account Payables reached $940000.0 in Q3 2025 per ASMB's latest filing, up from -$132000.0 in the prior quarter.
  • Across five years, Change in Account Payables topped out at $1.0 million in Q2 2022 and bottomed at -$1.3 million in Q1 2023.
  • Average Change in Account Payables over 5 years is -$153421.1, with a median of -$146000.0 recorded in 2023.
  • Peak YoY movement for Change in Account Payables: tumbled 586.71% in 2021, then skyrocketed 1677.42% in 2022.
  • A 5-year view of Change in Account Payables shows it stood at $31000.0 in 2021, then surged by 1677.42% to $551000.0 in 2022, then plummeted by 153.9% to -$297000.0 in 2023, then plummeted by 152.53% to -$750000.0 in 2024, then surged by 225.33% to $940000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Account Payables were $940000.0 in Q3 2025, -$132000.0 in Q2 2025, and $290000.0 in Q1 2025.